These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 18164420)
21. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Gotthardt M; Battmann A; Höffken H; Schurrat T; Pollum H; Beuter D; Gratz S; Béhé M; Bauhofer A; Klose KJ; Behr TM Nucl Med Commun; 2004 May; 25(5):439-43. PubMed ID: 15100501 [TBL] [Abstract][Full Text] [Related]
22. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. de Groot JW; Links TP; Jager PL; Kahraman T; Plukker JT Ann Surg Oncol; 2004 Aug; 11(8):786-94. PubMed ID: 15289241 [TBL] [Abstract][Full Text] [Related]
23. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the thyroid]. Bourguet P; Bull Cancer; 2003 Feb; 90 Spec No():S105-9. PubMed ID: 12739343 [No Abstract] [Full Text] [Related]
24. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Musholt TJ; Musholt PB; Dehdashti F; Moley JF Surgery; 1997 Dec; 122(6):1049-60; discussion 1060-1. PubMed ID: 9426419 [TBL] [Abstract][Full Text] [Related]
25. Would patient selection based on both calcitonin blood level and doubling time improve 18F-FDG PET sensitivity in restaging of medullary thyroid cancer? Aide N; Bardet S J Nucl Med; 2007 Sep; 48(9):1574; author reply 1574-5. PubMed ID: 17785732 [No Abstract] [Full Text] [Related]
26. ¹⁸F-FDG and new positron emitter radiotracers for detecting recurrent medullary thyroid carcinoma. Marzola MC; Rubello D J Med Imaging Radiat Oncol; 2012 Apr; 56(2):132-5. PubMed ID: 22498183 [No Abstract] [Full Text] [Related]
27. Functional nuclear medicine imaging of medullary thyroid cancer. Bozkurt MF; Uğur O; Banti E; Grassetto G; Rubello D Nucl Med Commun; 2008 Nov; 29(11):934-42. PubMed ID: 18836370 [TBL] [Abstract][Full Text] [Related]
28. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613 [TBL] [Abstract][Full Text] [Related]
29. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Nanni C; Rubello D; Fanti S; Farsad M; Ambrosini V; Rampin L; Banti E; Carpi A; Muzzio P; Franchi R Biomed Pharmacother; 2006 Sep; 60(8):409-13. PubMed ID: 16891093 [TBL] [Abstract][Full Text] [Related]
30. Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid carcinoma. Esik O; Szavcsur P; Szakáll S; Bajzik G; Repa I; Dabasi G; Füzy M; Szentirmay Z; Perner F; Kásler M; Lengyel Z; Trón L Cancer; 2001 Jun; 91(11):2084-95. PubMed ID: 11391589 [TBL] [Abstract][Full Text] [Related]
31. Avid 18F-FDG uptake in rectal hemorrhoid in a patient with metastatic medullary carcinoma of thyroid. Basu S; Nair N Indian J Gastroenterol; 2006; 25(5):257. PubMed ID: 17090847 [No Abstract] [Full Text] [Related]
32. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Diehl M; Risse JH; Brandt-Mainz K; Dietlein M; Bohuslavizki KH; Matheja P; Lange H; Bredow J; Körber C; Grünwald F Eur J Nucl Med; 2001 Nov; 28(11):1671-6. PubMed ID: 11702109 [TBL] [Abstract][Full Text] [Related]
33. A rare case of medullary carcinoma thyroid metastasizing to bilateral breast parenchyma. Hassan A; Siddiqui M; Jahangir S Nucl Med Rev Cent East Eur; 2016; 19(B):17-19. PubMed ID: 27900756 [TBL] [Abstract][Full Text] [Related]
34. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. Robbins RJ; Wan Q; Grewal RK; Reibke R; Gonen M; Strauss HW; Tuttle RM; Drucker W; Larson SM J Clin Endocrinol Metab; 2006 Feb; 91(2):498-505. PubMed ID: 16303836 [TBL] [Abstract][Full Text] [Related]
35. Detection of thyroid malignancy in a hot nodule by fluorine-18-fluorodeoxyglucose positron emission tomography. Low SC; Sinha AK; Sundram FX Singapore Med J; 2005 Jun; 46(6):304-7. PubMed ID: 15902360 [TBL] [Abstract][Full Text] [Related]
36. Targeting Amyloids with [ Li C; Zhang P; Nie R; Gong X; Xie J; Yu Z; Wang C; Zhang H; Yan R; Lu Z Mol Pharm; 2022 Feb; 19(2):584-591. PubMed ID: 34982563 [TBL] [Abstract][Full Text] [Related]
37. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer? Schaefferkoetter JD; Carlson ER; Heidel RE J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746 [TBL] [Abstract][Full Text] [Related]
38. Thyroid metastasis from colorectal cancer: role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Malani AK; Gupta C; Rangineni S; Gupta V Clin Colorectal Cancer; 2005 Nov; 5(4):287-91. PubMed ID: 16356308 [TBL] [Abstract][Full Text] [Related]
39. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315 [TBL] [Abstract][Full Text] [Related]
40. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma. Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]